Trial Profile
Efficacy Study of the Quadrivalent Human Papilloma Virus (HPV) Vaccine to Prevent Recurrence of External Genital Warts (EGW) in Patients Who Were Cured in the First Place
Status:
Recruiting
Phase of Trial:
Phase III
Latest Information Update: 05 Nov 2021
Price :
$35
*
At a glance
- Drugs Human papillomavirus vaccine recombinant quadrivalent Merck (Primary)
- Indications Genital warts
- Focus Therapeutic Use
- Acronyms CONDYVAC
- 26 Feb 2018 Status changed from not yet recruiting to recruiting.
- 22 Dec 2016 New trial record